Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165031 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04165031 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 5 participants.
The verdict
NCT04165031, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
Interventions
- DRUG Docetaxel
- DRUG Cetuximab
- DRUG Abemaciclib
- DRUG Erlotinib
- DRUG LY3499446
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-11-28 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165031
The ClinicalTrials.gov registry entry for NCT04165031 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT04165031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04165031 about?
NCT04165031 is a clinical study titled "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation". The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
What is the current status of trial NCT04165031?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-11-28. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04165031?
The interventions under investigation include: Docetaxel (DRUG), Cetuximab (DRUG), Abemaciclib (DRUG), Erlotinib (DRUG), LY3499446 (DRUG).
Who is sponsoring clinical trial NCT04165031?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.